Medtronic plc. (NYSE:MDT) has achieved yet another milestone as it continues to strengthen its position as a leader in the detection and treatment of atrial fibrillation (AF). The company’s Reactive ATP therapy successfully slowed the progression of AF in patients with implanted cardiac devices, in a trial carried out on 8,800 patients.
Reactive ATP Therapy Results
The positive results build on the MINERVA trial that found Reactive ATP therapy significantly reduced AF disease progression when used with pacemakers. The therapy has also been found to significantly reduce AF-related hospitalizations as well as emergency department visits.
“These are the first real-world data on the clinical impact of Reactive ATP therapy and the first in patients with ICDs and CRT devices. These data have important implications for all device patients because of the high prevalence of AF and the correlation of disease progression to worsened patient outcomes,” said Mr. Giuseppe Boriani
Atrial Fibrillation is a progressive disease that impairs life while increasing the risk of hospitalization among patients using cardiac devices. It currently afflicts over 33 million people worldwide. Medtronic has sought to curb the spread of AF by encouraging the use Reactive ATP therapy, which is an advanced painless pacing therapy. The company’s devices send pacing pulses to the atria thus restoring normal heart rhythm.
Medtronic has teamed up with leading clinicians and researchers to offer its broad range of innovative medical technologies for the treatment of the cardiovascular diseases.
Canada Diabetes Facility
Separately, Medtronic has expanded its footprint in Canada with the opening of a resource center for diabetes patients. Located in Surrey, the facility will serve as a one-stop shop for people struggling with diabetes. In addition to providing support in between clinic visits, the facility will offer insulin pump classes.
Patients will be educated on how to carry out carb counting and best travel practices. Networking opportunities and one-on-one time with insulin pump trainers will also come in . Medtronic expects the facility to raise the bar when it comes to the kind of services that diabetes patients receive.
Shares of Medtronic were up by 0.48% in Friday’s trading session ending the week at $88.08 a share.
